Welichem Biotech has developed a small molecule drug candidate, WBI-1001, that selectively
targets the pathogenic features of inflammatory skin diseases, including atopic dermatitis (a
form of eczema).The purpose of this clinical trial is to further test the safety and efficacy
of WBI-1001 as a topically applied cream over an extended period of 12 weeks on patients with
mild to moderate atopic dermatitis.